ASX 200 morning report – BBN, CSL & QBE shares in focus
Drew Meredith, CFP
August 16, 2021
The S&P/ASX 200 (ASX:XJO) finished at another record high on
CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The S&P/ASX 200 (ASX:XJO) finished at another record high on
The S&P/ASX 200 (ASX: XJO) charged 2% higher for the
The S&P/ASX 200 (ASX: XJO) managed to deliver another positive
Growing global outbreaks of the Delta strain have shaken markets
The S&P/ASX 200 (ASX:XJO) strengthened throughout the day to finish
The S&P/ASX 200 (ASX: XJO) managed a 0.2% gain on
The S&P/ASX 200 (ASX:XJO) fell 0.3% on Thursday as Woolworths
Shares in healthcare giant CSL Limited (ASX: CSL) have made
The S&P/ASX 200 (ASX: XJO) followed global markets lower to
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
